Danaher Corporation reported second quarter 2026 results with net earnings of $870 million, or $1.23 per diluted common share, representing a 60% year-over-year increase. Revenues rose 5.5% to $6.3 billion. Non-GAAP adjusted diluted net earnings per share grew 8.0% to $1.94. Operating cash flow reached $1.5 billion, while non-GAAP free cash flow was $1.3 billion. Following the earlier-than-anticipated completion of the Masimo acquisition, the company raised its full year 2026 adjusted diluted net earnings per share guidance to a range of $8.45 to $8.60. Danaher also announced its intention to acquire StatLab, a histology workflow manufacturer, by the end of 2026. Danaher is a global life sciences and diagnostics company.

Danaher Corporation and its subsidiary, DH Masi Finance Inc., entered into a note purchase agreement to issue seven series of senior notes with aggregate principal amounts totaling CHF 2,382,940,000. The notes feature interest rates ranging from 1.65% to 2.51% and maturities spanning from 2031 to 2056. The company intends to use the net proceeds for general corporate purposes, such as acquisitions and share repurchases.

Danaher Corporation shareholders approved the Amended and Restated Danaher Corporation Omnibus Incentive Plan at the company's annual meeting on May 5, 2026. The approved plan increases the company's share reserve by 20 million shares of common stock and extends the plan's term to May 5, 2036.

Danaher Corporation issued €3 billion in aggregate principal amount of senior notes, consisting of floating rate and fixed rate notes maturing between 2028 and 2038. The company realized approximately €2.98 billion in net proceeds, which it intends to use primarily to fund the acquisition of Masimo Corporation and for general corporate purposes.

Danaher Corporation entered into a new $5.0 billion 364-day revolving credit facility with Bank of America and a syndicate of lenders. The facility is intended to provide liquidity support for the company's U.S. dollar-denominated commercial paper program and for general corporate purposes.